Ultime notizie per Intelligent Group (NASDAQ:INTJ) Azioni

Intelligent Group

Intelligent Group Ltd is a professional services provider in Hong Kong that principally engages in the provision of Financial PR services. The company provides a substantial number of holistic and comprehensive Financial PR services to its clients through its key operating entity in Hong Kong. It advises its clients on their communications and reputation management efforts. Its Financial PR services include creating multi-stakeholder communications programs, arranging press conferences and interviews, participating in the preparation of news releases and shareholders' meetings, monitoring news publications, identifying shareholders, targeting potential investors, organizing corporate events, and implementing crisis management policies and procedures.

Intelligent Group Limited - Class A Ordinary Shares

Intelligent Group Ltd

<a href="https://www.ft.com/content/b649cb3d-9156-4e0c-9e6f-7458b670e97b" title="https://www.ft.com/content/b649cb3d-9156-4e0c-9e6f-7458b670e97b">https://www.ft.com/content/b649cb3d-9156-4e0c-9e6f-7458b670e97b</a>

Macro Economic Events

News

Global

Economics

ORCL

SNAP

'Tucker Carlson was on White House list of potential TikTok investors' - Financial Times

Goldman Sachs has initiated coverage of generic pharmaceutical stocks, highlighting the sector's strong long-term <a href="https://www.benzinga.com/general/health-care">potential despite recent volatility</a>. 
Analyst Matt Dellatorre points to a mix of company-specific challenges—such as fiscal 2025 guidance—and broader industry concerns like tariffs and drug pricing. 
Still, he argues that many of these stocks are attractively valued and represent businesses well-positioned for growth.
See Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45819356/dogecoin-down-10-on-the-week-is-the-musk-trump-spat-bearish-for-doge">Dogecoin Down 10% On The Week: Is The Musk-Trump Spat Bearish For DOGE?</a>
<h2 class="wp-block-heading">Teva Pharmaceutical </h2>
Goldman Sachs has initiated Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy rating, with a <a href="https://www.benzinga.com/quote/TEVA/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $24</a>. 
Dellatorre sees an improvement in the core business, with an upside to consensus EBITDA estimates driven by strong growth in the branded segment.
On the generics side, Goldman Sachs expects limited growth over the next few years as an expanding biosimilar portfolio. Other new product launches are offset by the Revlimid settlement expiration in 2026.
The analyst expects robust growth on continued momentum for key assets on the branded side, acknowledging the industry-wide Part D re-design hit to <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" rel="noreferrer noopener">2025 growth and margins</a>.
Goldman views Teva&#8217;s biosimilar portfolio as an important long-term growth driver for the generics business. The company now has 10 in-line assets and 13 biosimilars in the pipeline. 2027 expects five potential launches in the U.S. and three in the EU/exUS.
Teva expects biosimilar revenue of around $400 million in fiscal 2024 to double by fiscal 2027.
Goldman writes that Teva&#8217;s branded pipeline represents a significant valuation lever. It sees a favorable catalyst path over the next 24 months. The analyst sees an attractive catalyst path, with multiple opportunities to re-rate as these pipeline assets are de-risked.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45297381/viatris-shares-positive-data-from-investigational-contraceptive-patch-fast-acting-meloxicam-reduces-opioid-use-in-surgery-pain-trials" rel="noreferrer noopener">Viatris Discloses Positive Data From 2 Drugs In Earnings Report, Stock Soars</a>
<h2 class="wp-block-heading">Viatris</h2>
Dellatorre initiated Viatris Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) with a Neutral rating and <a href="https://www.benzinga.com/quote/VTRS/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $10</a>. Why? There&#8217;s a lack of clarity on the growth outlook for the core business given current structural dynamics in the generics and branded segments.
More specifically, on the generics side, <a target="_blank" href="https://www.benzinga.com/25/05/45297381/viatris-shares-positive-data-from-investigational-contraceptive-patch-fast-acting-meloxicam-reduces-opioid-use-in-surgery-pain-trials" rel="noreferrer noopener">excluding Indore</a>, Goldman is optimistic about recent underlying trends and continues to monitor Viatris&#8217; ability to meaningfully offset price erosion via new product launches and progress on the ongoing portfolio optimization.
In the branded drugs segment, the analyst writes that older products losing market share in the U.S. and Asia have hurt growth, and it is watching for signs of recovery. However, there have been signs of stabilization in developed markets, China, and other emerging markets in recent quarters. Despite the decline, these products still generate steady cash, and Goldman is observing how the company reinvests this into new growth opportunities.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45175642/drug-maker-amneal-highlights-strong-commercial-uptake-for-parkinsons-drug-but-q1-earnings-are-mixed" rel="noreferrer noopener">Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson&#8217;s Drug But Q1 Earnings Are Mixed</a>
<h2 class="wp-block-heading">Amneal Pharmaceuticals&nbsp;</h2>
Goldman initiated Amneal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) with a Buy rating and a <a href="https://www.benzinga.com/quote/AMRX/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $12</a>.
The analyst is optimistic about the growth outlook for Amneal&#8217;s core business. He cites a strong product pipeline and track record of execution through various market environments.
Goldman has confidence in Amneal&#8217;s ability to continue to offset typical price erosion via new product launches. Amneal also has structural tailwinds as the company aggressively shifts its focus toward higher-value products.
In the branded segment, analyst Dellatorre is positive on the ongoing launch of the next-generation <a target="_blank" href="https://www.benzinga.com/25/04/44673049/amneals-combination-drug-shows-improved-sleep-quality-in-parkinsons-disease-patients" rel="noreferrer noopener">Parkinson&#8217;s disease drug</a> Crexont to ultimately offset Rytary&#8217;s 2025 loss of exclusivity and the endocrinology franchise&#8217;s stable growth outlook.
Price Action: TEVA stock is up 1.39% at $17.49, AMRX stock is up 2.37% at $7.34, and VTRS stock is up 2.07% at $8.64 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45800081/dr-reddys-and-alvotech-join-hands-to-develop-biosimilar-for-mercks-blockbuster-cancer-drug" target="_blank" rel="noreferrer noopener">Dr Reddy&#8217;s And Alvotech Join Hands To Develop Biosimilar For Merck&#8217;s Blockbuster Cancer Drug</a></li>
</ul>
Image: Shutterstock

Analyst Color

Biotech

Large Cap

Health Care

Price Target

Initiation

Analyst Ratings

General

AMRX

TEVA

VTRS

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?

G-III Apparel Group, LTD. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) shares are trading lower on Friday after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45810239/g-iii-apparel-group-ltd-reports-first-quarter-fiscal-2026-results" rel="noreferrer noopener">reported first-quarter</a> adjusted earnings per share of 19 cents, beating the analyst consensus estimate of 12 cents. Quarterly sales of $583.61 million (down 4% year over year), outpacing <a target="_blank" href="https://newsdesk.benzinga.com/calendar/earning" rel="noreferrer noopener">the Street view of $580.37 million</a>.
&#8220;Our performance was fueled by double-digit growth of our key owned brands, DKNY, Karl Lagerfeld and Donna Karan, which largely offset the exit of the Calvin Klein jeans and sportswear businesses,&#8221; said CEO Morris Goldfarb.&nbsp;
Gross profit in the quarter under review decreased to $246.544 million from $258.893 million a year ago. Operating profit decreased to $8.476 million from $13.504 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44648799/g-iii-apparel-group-could-weather-the-impact-of-tariffs-although-uncertainty-looms-analyst-says" rel="noreferrer noopener">This Apparel Group &#8216;Not In A Panic Mode&#8217; Over Trump Tariffs, Although Uncertainty Looms</a>
The DKNY parent said that the inventories decreased 5% to $456.5 million this year compared to $479.7 million last year.
The company exited the quarter with cash and equivalents worth $257.785 million, compared with $508.434 million a year ago. Total debt decreased 96% to $18.7 million this year compared to $426.4 million last year.
<h2 class="wp-block-heading">Outlook</h2>
Due to tariff and macro uncertainty, G-III Apparel withdraws FY26 profit guidance and sees a $135 million unmitigated tariff hit, mostly in the second half.
G-III Apparel Group affirms FY2026 sales guidance of $3.14 billion vs $3.12 billion estimate.
As previously planned, the company continues to expect sales to be lower in the first half of fiscal 2026 than in the previous year, with acceleration expected in the second half of fiscal 2026.
G-III Apparel Group expects second-quarter EPS of $0.02–$0.12 and revenue of approximately $570 million versus the $621 million estimate.
Price Action: GIII shares are trading lower by 15.10% to $23.51&nbsp;at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/45811173/rent-the-runway-q1-subscriber-growth-returns-eyes-double-digit-increase-in-fy25" target="_blank" rel="noreferrer noopener">Rent The Runway Q1 Subscriber Growth Returns, Eyes Double-Digit Increase In FY25</a></li>
</ul>
Image by Copenhagen Stock via Shutterstock

Earnings

Equities

Guidance

Markets

Movers

GIII

DKNY Parent Anticipates Tariff Hit, Withdraws Profit Outlook

Thursday&#8217;s <a href="https://www.benzinga.com/etfs/specialty-etfs/25/06/45804512/trump-musk-feud-gets-ugly-etfs-exposed-with-tesla-caught-in-the-crossfire">dramatic fight</a> between President Trump and Tesla CEO Elon Musk, his political ally and donor, sent Tesla stock down more than 14%.
This is just the latest episode in a long string of bad news for Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
The stock, which was trading at around $300 per share on Friday, is down 25% for the year but has gained 11% over the past three months. Poor domestic and international sales, as epitomized by Tesla&#8217;s market share in car-mad Germany being down 36% year-to-year, concerns over robot taxi safety after media reports of a fatal car crash involving Tesla's driver-assistance software and Musk's political forays have stacked the deck against the stock.
With Tesla&#8217;s future looking increasingly uncertain, investors looking to benefit from the rise of electric cars are starting to look elsewhere.
Even as EV sales grow, totaling 20% of new car sales in 2024 globally, the maladies holding EVs back are no secret. In 2025, subsidy schemes are winding down across the globe, tariff fears are fueling price hikes that challenge cash-challenged consumers, charging stations remain spotty, and lower oil prices have combined to throttle electric vehicle (EV) adoption.
Tesla&#8217;s woes are just one example of this trend.
It's been a bumpy ride for electric vehicle stocks near the midpoint of 2025, with the KraneShares Electric Vehicles Future Mobility Index benchmark ETF up 2.0% in 2025. The fund, which tracks the Bloomberg Electric Vehicle Index, has been a portfolio drainer for a while now—down over 15% over the past three years.
One saving grace of late is China, where low battery prices, attractive trade-in deals, and a supportive government have helped EV sales rise by 40% in 2024 on a year-to-year basis. By the end of 2024, China accounted for two-thirds of all worldwide EV sales – that's up from half of all sales in 2021, according to the<a href="https://www.iea.org/reports/global-ev-outlook-2025/trends-in-electric-car-markets-2"> International Energy Agency's Global EV Outlook for 2025</a>.
"The EV market will continue to depend upon a mix of subsidies, incentives, and favorable trade policies," said David Nicholson, chief technology advisor at The Futurum Group in San Francisco, Cal. "Against this backdrop, Chinese EV manufacturers will face varying levels of protectionism. That will be the dominant theme moving forward. &#8220;How much will the rest of the world allow China to access its EV consumers?&#8221;
With EV long-term prospects on more solid footing against 2025 share price woes, which electric vehicle stocks resonate in 2025? Here's a snapshot.
<h2 class="wp-block-heading">Wall Street's Elite Are Betting Big on These Stocks</h2>
What's Wall Street buying right now? Benzinga Edge gives you instant access to ratings from 1,000 top analysts. From Goldman Sachs to Morgan Stanley and more—discover which stocks the smart money is piling into…and potentially profit alongside them. Unlock All Wall Street Stock Ratings <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/">HERE</a>
<h2 class="wp-block-heading">Tesla Inc.</h2>
Many of Tesla's current problems are short-term, with tariffs and political skirmishes involving Musk having only so much staying power. That doesn't mean Tesla is in a good spot, particularly with the proposed "Big Beautiful Bill" recently passed by the U.S. House of Representatives, which is looking to clear the Senate in June and appears to have set off the Musk-Trump feud. Among other features, the legislation curbs or, in some cases, outright eliminates EV and green energy tax credits introduced in 2022's Inflation Reduction Act. 
That's not good news for EV giants like Tesla, which count on credits to move vehicles. According to J.P. Morgan analyst Ryan Brinkman, if the tax act is passed with the EV credits neutered, Tesla could cost $2 billion. Brinkman has a sell call on TSLA, with a steep 65% slide in Tesla stock in play the following year.
However, if you have full confidence in Tesla's ability to bring new transport technologies like robot taxis to the market, then Tesla makes sense.
"Tesla&#8217;s value is based more upon future expectations of their ability to deliver in AI and Robotics than it is based on a realistic assessment to grow market share in vehicle sales," Nicholson said. "If you believe in the robotics story in particular, you buy or hold Tesla stock."
<h2 class="wp-block-heading">BYD Co. Ltd.&nbsp;</h2>
BYD (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>), China's leading EV manufacturer, is conducting a cost-cutting campaign amid a slowing Chinese economy, expanded in-country electric vehicle competition, and collapsing EV sales in Europe. These factors are weighing heavily on China's auto manufacturing sector.
Yet BYD continues to dodge the deluge. The stock is up 53.18% year-to-date and up 6% over the past month, as the Shenzhen-based automaker has cut prices on 22 EV and hybrid vehicle models and will continue to do so through the end of June. Speculation is rising that BYD will continue to keep its EV price tags lower as it eventually edges into the US market, which would constitute a big problem for Tesla and major US automakers.
Analysts are backing the stock, with Macquarie holding its Buy Rating on BYD, according to a late May research note, and Erste Group initiating coverage with a Buy.
<h2 class="wp-block-heading">Rivian Automotive Inc.</h2>
Rivian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) has been picking up steam lately, with its stock price up 23% over the past three months, and it has an intriguing story to tell. The EV manufacturer is aiming for the SUV and truck-driving consumer, which can be a tough sell in a downbeat economy. The numbers back that sentiment up, with deliveries down from 51,000 in 2024 to an estimated range of 40,000 to 46,000 in 2025, as high prices keep would-be buyers on the sidelines.
Yet RIVN is making strides in other areas. The company has a big delivery van deal with Amazon and has partnered with Volkswagen in a $5.8 billion software and services deal that helped RIVN net $167 million in the first quarter of 2025.
Revenues were up 3% for the first quarter of 2025 and the company has recorded two straight quarters of gross profit and production on its lower-cost R2 EV model (costs clocked in at $45,000 compared to $76,000 for Rivian's R1 line).
Rivian investors may have to show patience for a company focused on the long haul, but analysts see a big upside. Exhibit A is Exane BNB Paribas' James Picariello, who recently issued a Buy rating on the stock with a $20 price target, up above 40% from where the stock is trading as of writing.
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

Trading Ideas

BYDDY

RIVN

TSLA

Top 2 Alternatives To Tesla After The Musk-Trump Breakup

We are offering 2,250,000 shares of our common stock (or 2,587,500 shares if the underwriters exercise the overallotment option described below), par value $0.0001 per share (the "common stock"), at a public offering price per share of $8.00.
&nbsp;
Our common stock is listed under the symbol "BMNR" on the NYSE American.
&nbsp;
&nbsp;
The share and per share information in this prospectus, unless otherwise noted and other than in our financial statements and the notes thereto, reflect the reverse stock split of our outstanding shares of common stock at a 1-for-20 ratio pursuant to the filing of a&nbsp;Certificate of Amendment to our Amended and Restated Certificate of Incorporation on May 15, 2025.
&nbsp;

Offerings

BMNR

BMNR Announces Public Offering Of 2.25M Shares At $8.00 Each

<a href="https://www.businessinsider.com/amazon-freezes-hiring-budget-retail-business-this-year-2025-6" title="https://www.businessinsider.com/amazon-freezes-hiring-budget-retail-business-this-year-2025-6">https://www.businessinsider.com/amazon-freezes-hiring-budget-retail-business-this-year-2025-6</a>

Management

AMZN

'Amazon Freezes Hiring Budget For Its Big Retail Business This Year' - Business Insider Exclusive

Rubrik, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) shares are trading on volatility Friday. The company repotted better-than-expected first-quarter financial results and issued second-quarter guidance above estimates on Thursday after the <a href="https://www.benzinga.com//node/45802271">market closed.</a>
The Details: Rubrik reported an adjusted loss of 15 cents per share, beating the consensus estimate of a 32 cent-loss. In addition, the company reported sales of $278.48 million, beating the consensus estimate of $260.35 million, and representing a 49% year-over-year growth.
Rubrik announced subscription annual reoccurring revenue grew 38% year-over-year to $1.89 billion.
The company ended the quarter with $762.1 million in cash, cash equivalents and short term investments.
Outlook: The company expects an adjusted loss per share of 33 to 35 cents for the second quarter, versus the 36-cent loss expected by analysts. Furthermore, it anticipates sales from $281 million to $283 million, versus the consensus estimate of $273.59 million.
The company now sees an adjusted loss per share from $1.02 to 96 cents for the fiscal-year, versus the consensus estimate of a $1.15 loss. It previously expected a loss between $1.23 and $1.13.
The company expects sales from $1.18 billion to $1.19 billion, versus the consensus estimate of $1.16 billion. It previously saw sales from $1.15 billion to $1.16 billion.
Analyst Changes: Following the earnings report, multiple analysts <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=http://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45813574/these-analysts-boost-their-forecasts-on-rubrik-after-better-than-expected-q1-results&amp;ved=2ahUKEwjUobnujt2NAxVrmokEHVHfAWUQFnoECCUQAQ&amp;usg=AOvVaw0nTKSuroqaGfjZTQ8f4E2h">issued price target adjustments</a>.
<ul class="wp-block-list">
<li>Guggenheim analyst John Difucci maintained a Buy rating on Rubrik and raised the price target from&nbsp;$105&nbsp;to&nbsp;$108.</li>
<li>Truist Securities analyst Joel Fishbein maintained a Buy rating on Rubrik and raised the price target from&nbsp;$90&nbsp;to&nbsp;$110.</li>
<li>Baird analyst Shrenik Kothari maintained an Outperform rating on Rubrik and raised the price target from&nbsp;$95&nbsp;to&nbsp;$110.</li>
<li>Wells Fargo analyst Andrew Nowinski maintained an Overweight rating on Rubrik and raised the price target from&nbsp;$80&nbsp;to&nbsp;$125.</li>
<li>Cantor Fitzgerald analyst Jonathan Ruykhaver maintained an Overweight rating on Rubrik and raised the price target from&nbsp;$95&nbsp;to&nbsp;$115.</li>
</ul>
See Also: <a href="https://www.benzinga.com/markets/large-cap/25/06/45817251/rio-tinto-opens-2b-pilbara-iron-ore-mine-with-chinas-baowu">Rio Tinto Opens $2B Pilbara Iron Ore Mine With China&#8217;s Baowu</a>
RBRK Price Action: At the time of writing, Rubrik stock is trading 1.02% lower at $97.57, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjT9p_c_NyNAxWok4kEHbkOLfYQFnoECBEQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Image: via Shutterstock

RBRK

What's Going On With Rubrik Stock Friday?

Wall Street surged into rally mode during the final trading session of the week as better-than-expected jobs data helped ease fears <a href="https://www.benzinga.com/markets/economic-data/25/06/45818251/trump-cheers-strong-jobs-data-renews-attack-on-feds-powell-rates-should-be-much-lower">of an economic slowdown.</a>
In May, nonfarm payrolls increased by 139,000—a slight dip from April's downwardly revised 147,000, but above economist forecasts of 130,000. The unemployment rate held steady at 4.2%, while wage growth beat expectations, signaling a potential<a href="https://www.benzinga.com/markets/economic-data/25/06/45812372/us-labor-markets-defies-tariff-concerns-as-nonfarm-payrolls-wages-top-expectations-in-may"> boost to consumer spending.</a>
The S&amp;P 500 rose 0.9% nearing the 6,000 mark, its highest level since Feb. 24. The Nasdaq 100 climbed 1% to over 21,720, putting tech stocks within striking distance—just 2 percentage points—of record highs.
In equities, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rebounded 5.6%, partially recovering from Thursday's 14% plunge triggered by a high-profile clash between Elon Musk and President Donald Trump. Cooler rhetoric on Friday helped sentiment, after the White House said no call between Trump and Musk was currently planned.
Stronger-than-expected economic data also lifted the U.S. dollar and Treasury yields, with the 10-year yield climbing 10 basis points to 4.5%.
Gold dropped 0.9% to $3,321, heading for its worst session of the week. In contrast, crude oil rallied 2.5% to nearly $65 a barrel—its highest since early April—on signs of easing geopolitical risk as Trump and Chinese President Xi Jinping agreed to meet, calming market fears of a renewed tariff war that could dent global energy demand.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) advanced 3.4% to $105,000, nearly erasing Thursday's decline.
Read also: <a href="https://www.benzinga.com/news/politics/25/06/45817556/trump-musk-feud-sends-betting-markets-into-overdrive-heres-what-traders-see-next">Trump-Musk Feud Sends Betting Markets Into Overdrive: Here&#8217;s What Traders See Next</a>
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg (%)</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,126.31</td>
<td>1.4%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,727.92</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,993.56</td>
<td>0.9%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,648.75</td>
<td>0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:40 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.8% to $597.90.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.8% to $427.22.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.9% to $529.17.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 1.4% to $211.34.</li>
<li>The&nbsp;Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 2%; the&nbsp;Utilities&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 0.1%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
<ul class="wp-block-list">
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) fell 4% despite slightly beating the Street&#8217;s estimates on both sales and earnings last quarter.</li>
<li>Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) tumbled 20% as strong first-quarter results were overshadowed by a lowered full-year profit outlook, driven by rising tariff costs and increased markdowns.</li>
<li>Other stocks reacting to earnings included DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) down 18.4%, Vail Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) down 3.7%, Samsara Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>), down 4.9% and ABM Industries Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) down 14.5%. </li>
</ul>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/commodities/25/06/45819573/silver-tops-36-triggering-a-generational-technical-breakout">Silver Tops $36, Triggering A Generational Technical Breakout </a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Government

Regulations

Broad U.S. Equity ETFs

Small Cap

Treasuries

Econ #s

Tech

ETFs

$BTC

AVGO

SPDR Dow Jones Industrial Average ETF Trust

DOCU

LULU

Select Sector SPDR-Consumer Discretionary

Stocks Rally On Strong Jobs Numbers; Tesla Rebounds As Trump-Musk Feud Softens: What's Driving Markets Friday?

Raymond James analyst Sam Darkatsh maintains Toro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>) with a Outperform and lowers the price target from $95 to $90.

Raymond James Maintains Outperform on Toro, Lowers Price Target to $90

Raymond James analyst Brian Peterson maintains Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) with a Outperform and lowers the price target from $48 to $43.

BRZE

Raymond James Maintains Outperform on Braze, Lowers Price Target to $43

Oppenheimer analyst Ittai Kidron maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Outperform and raises the price target from $225 to $250.

SNOW

Oppenheimer Maintains Outperform on Snowflake, Raises Price Target to $250

Federal Reserve

Live On CNBC, Fed's Harker Says Sees Steadiness In 'Solid' Latest Job Data; Much Of Tariff Impacts Yet To Be Felt; Fed Interest Rate Policy Is Modestly Restrictive; Now Is Time For Fed To Hold Steady And Watch Data

Oppenheimer analyst Ittai Kidron maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Outperform and raises the price target from $290 to $345.

Oppenheimer Maintains Outperform on Zscaler, Raises Price Target to $345

BRLS

Borealis Foods Shares Halted On Circuit Breaker To The Downside, Stock Now Up 80%

WIIM

CYCU

Cycurion shares are trading lower after the company reported a Q1 EPS miss.

Oppenheimer analyst Leland Gershell initiates coverage on Climb Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLYM#NASDAQ">CLYM</a>) with a Outperform rating and announces Price Target of $10.

CLYM

Oppenheimer Initiates Coverage On Climb Bio with Outperform Rating, Announces Price Target of $10

Insider Trades

Abacus Global Management Form4 Filing Shows President Kevin Scott Kirby Bought 86,207 Shares At An Average Price Of $5.77/Share; President Sean McNealy Bought 86,207 Shares At An Average Price Of $5.77/Share

Oppenheimer analyst Brian Schwartz maintains Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) with a Outperform and lowers the price target from $51 to $44.

Oppenheimer Maintains Outperform on Braze, Lowers Price Target to $44

NVNO

enVVeno Medical shares are trading higher after the company announced its interim two-year follow-up data on the VenoValve trial.

Abacus Global Management Form4 Filing Shows CFO William Hugh McCauley Bought 33,000 Shares At An Average Price Of $5.82/Share

Press Releases

Intelligent Joy Limited Signs Strategic Cooperation MOU with First U.S. Capital Group

Intelligent Joy Limited Signs MOU for Strategic Cooperation with First U.S. Capital Group (Revised)

Intelligent Joy Limited Signs MOU with Smart IR and CLS Press to Collaborate on AI-Driven Investor Relations Platform

Comments

Intelligent Group

Notizie

Ultime notizie per Intelligent Group (NASDAQ:INTJ) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO